Home Capital Broker's Calls

Analysts mixed on UG Healthcare following halt in glove production due to EMCO

Atiqah Mokhtar
Atiqah Mokhtar7/13/2021 5:11 PM GMT+08  • 3 min read
Analysts mixed on UG Healthcare following halt in glove production due to EMCO
RHB and CGS-CIMB have retained their respective 'neutral' and 'add' ratings for UG Healthcare.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Analysts from RHB Group Research and CGS-CIMB Research have given mixed reactions to UG Healthcare’s announcement on July 12 that it was halting operations of its manufacturing plants in Seremban temporarily due to Malaysia's Enhanced Movement Control Order (EMCO) from July 9 to July 22.

See also: UG Healthcare to see further 2.4% drop in glove production due to EMCO

RHB’s Singapore research team views the development as negative to UG Healthcare’s near-term earnings. The company disclosed that the plant closure will affect its production by 80 million pieces of gloves, or 2.35% of total production.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.